Mana.bio
Tel Aviv, Israel· Est.
AI‑powered platform that designs and validates novel lipid nanoparticles for targeted nucleic‑acid delivery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered platform that designs and validates novel lipid nanoparticles for targeted nucleic‑acid delivery.
Gene TherapyVaccinesRNA Therapeutics
Technology Platform
AI‑driven design of lipid nanoparticle formulations combined with high‑throughput synthesis and automated screening to produce tissue‑targeted, extra‑hepatic delivery vehicles.
Opportunities
The platform can accelerate the development of tissue‑specific RNA therapeutics, unlocking large markets in oncology, rare diseases, and vaccines beyond hepatic delivery.
Risk Factors
Technical risk in achieving robust extra‑hepatic targeting, regulatory uncertainty for novel delivery systems, and competition from established LNP developers.
Competitive Landscape
Competitors include Moderna, BioNTech, Alnylam, and Arrowhead, which focus on hepatic LNPs; Mana.bio differentiates through AI‑guided, tissue‑targeted LNP design and rapid iterative screening.